{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-017065","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.267520+00:00","generated_at":"2026-06-26T02:20:23.708662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ARCA biopharma Q1 net loss narrows to $3.3M; initiates strategic review","bullets":["Net loss of $3.3M ($0.23/share) vs $4.1M ($0.33/share) in Q1 2021, narrowing on lower R&D spend.","Cash $49.1M as of March 31, 2022, expected to fund operations through mid-2023.","R&D expenses fell to $2.2M from $2.9M due to completion of rNAPc2 Phase 2b enrollment in Q4 2021.","Board established Special Committee in April to evaluate strategic options including partnering or other alternatives.","No revenue reported; clinical-stage biotech focused on genetically targeted cardiovascular therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-017065","json":"https://secwatch.observer/filing/0001564590-22-017065.json","markdown":"https://secwatch.observer/filing/0001564590-22-017065.md","text":"https://secwatch.observer/filing/0001564590-22-017065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022017065/0001564590-22-017065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022017065/abio-8k_20220502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:20:23.708662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}